AU2020451061A1 - Combination of ruxolitinib with INCB057643 for treatment of myeloproliferative neoplasms - Google Patents

Combination of ruxolitinib with INCB057643 for treatment of myeloproliferative neoplasms Download PDF

Info

Publication number
AU2020451061A1
AU2020451061A1 AU2020451061A AU2020451061A AU2020451061A1 AU 2020451061 A1 AU2020451061 A1 AU 2020451061A1 AU 2020451061 A AU2020451061 A AU 2020451061A AU 2020451061 A AU2020451061 A AU 2020451061A AU 2020451061 A1 AU2020451061 A1 AU 2020451061A1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
day
compound
ruxolitinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020451061A
Other languages
English (en)
Inventor
Phillip C. Liu
Matthew Stubbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AU2020451061A1 publication Critical patent/AU2020451061A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020451061A 2020-06-03 2020-09-14 Combination of ruxolitinib with INCB057643 for treatment of myeloproliferative neoplasms Pending AU2020451061A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034214P 2020-06-03 2020-06-03
US63/034,214 2020-06-03
PCT/US2020/050753 WO2021247064A1 (en) 2020-06-03 2020-09-14 Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms

Publications (1)

Publication Number Publication Date
AU2020451061A1 true AU2020451061A1 (en) 2022-12-15

Family

ID=72659928

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020451061A Pending AU2020451061A1 (en) 2020-06-03 2020-09-14 Combination of ruxolitinib with INCB057643 for treatment of myeloproliferative neoplasms

Country Status (23)

Country Link
EP (2) EP4161528B1 (cg-RX-API-DMAC10.html)
JP (2) JP7669396B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230031242A (cg-RX-API-DMAC10.html)
CN (1) CN115835868A (cg-RX-API-DMAC10.html)
AU (1) AU2020451061A1 (cg-RX-API-DMAC10.html)
CA (1) CA3184633A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022003409A1 (cg-RX-API-DMAC10.html)
DK (1) DK4161528T3 (cg-RX-API-DMAC10.html)
ES (1) ES3058891T3 (cg-RX-API-DMAC10.html)
FI (1) FI4161528T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20251457T1 (cg-RX-API-DMAC10.html)
IL (1) IL298200A (cg-RX-API-DMAC10.html)
LT (1) LT4161528T (cg-RX-API-DMAC10.html)
MA (1) MA59868B1 (cg-RX-API-DMAC10.html)
MD (1) MD4161528T2 (cg-RX-API-DMAC10.html)
MX (1) MX2022015220A (cg-RX-API-DMAC10.html)
PH (1) PH12022553276A1 (cg-RX-API-DMAC10.html)
PL (1) PL4161528T3 (cg-RX-API-DMAC10.html)
PT (1) PT4161528T (cg-RX-API-DMAC10.html)
RS (1) RS67440B1 (cg-RX-API-DMAC10.html)
SI (1) SI4161528T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202600021T1 (cg-RX-API-DMAC10.html)
WO (1) WO2021247064A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251457T1 (hr) * 2020-06-03 2026-01-02 Incyte Corporation Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi
EP4297750A1 (en) * 2021-02-25 2024-01-03 Impact Biomedicines, Inc. Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
WO2024039883A2 (en) * 2022-08-19 2024-02-22 Translational Drug Development Llc Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms
WO2024144258A1 (ko) * 2022-12-28 2024-07-04 주식회사 삼양홀딩스 룩소리티닙의 다중 방출제어 정제 조성물 및 이의 제조 방법
EP4734995A1 (en) * 2023-06-28 2026-05-06 Board of Regents, The University of Texas System Quinoline carboxamides for use in the treatment of mpn

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
SMT202000133T1 (it) * 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
CN109715625B (zh) 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
HRP20251457T1 (hr) * 2020-06-03 2026-01-02 Incyte Corporation Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi

Also Published As

Publication number Publication date
JP2025111539A (ja) 2025-07-30
IL298200A (en) 2023-01-01
MD4161528T2 (ro) 2026-03-31
PH12022553276A1 (en) 2024-02-19
DK4161528T3 (da) 2025-11-24
JP2023529365A (ja) 2023-07-10
CL2022003409A1 (es) 2023-05-26
PT4161528T (pt) 2026-01-23
FI4161528T3 (fi) 2025-12-12
KR20230031242A (ko) 2023-03-07
PL4161528T3 (pl) 2026-03-16
EP4161528A1 (en) 2023-04-12
RS67440B1 (sr) 2025-12-31
HRP20251457T1 (hr) 2026-01-02
SI4161528T1 (sl) 2026-01-30
WO2021247064A1 (en) 2021-12-09
MX2022015220A (es) 2023-03-08
CN115835868A (zh) 2023-03-21
EP4691563A3 (en) 2026-04-01
CA3184633A1 (en) 2021-12-09
ES3058891T3 (en) 2026-03-13
SMT202600021T1 (it) 2026-03-09
EP4691563A2 (en) 2026-02-11
JP7669396B2 (ja) 2025-04-28
LT4161528T (lt) 2026-02-10
EP4161528B1 (en) 2025-11-05
MA59868B1 (fr) 2025-11-28

Similar Documents

Publication Publication Date Title
EP4161528B1 (en) Combination of ruxolitinib with incb057643 for use in the treatment of myeloproliferative neoplasms
US20260137695A1 (en) Combination therapy for treatment of myeloproliferative neoplasms
EP4410375A2 (en) Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
CN110913861B (zh) G1t38的形态学形式及其制造方法
EP2593139B1 (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
CN113384546A (zh) 鲁索利替尼的缓释剂型
CN116157403B (zh) 曲拉西利的形态及其制造方法
KR20190130644A (ko) 항암 조합 요법
CN118201615A (zh) 喹唑啉酮化合物用于治疗癌症的新用途
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
KR20240016298A (ko) 재발성 원발성 cns 신생물에 대한 용도 및 방법
JP2025061387A (ja) 複素環式タンパク質キナーゼ阻害剤を含む製剤
CN115038447A (zh) 用于治疗癌症的组合疗法
US20230165863A1 (en) Methods and formulations for administration of thiocarbamate deriviatives a2a inhibitors
US12268786B2 (en) Methods of improving the solubility and bioavailability of therapeutic agents
HK40112852A (en) Pharmaceutical for treating or preventing cancer
TW202608439A (zh) 治療具有ａｓｘｌ１突變之個體之癌症的方法
HK40112620A (en) Novel use of quinazolinone compound for the treatment of cancer
TW202535398A (zh) 用於治療癌症之包含光學活性氮雜雙環衍生物之醫藥
CN112294814A (zh) 用于治疗胶质母细胞瘤的喹啉衍生物